Perioperative chemotherapy for bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 57, Issue 2, 2006, Pages 133-144

  Sonpavde, Guru ^a,c,d   Petrylak, Daniel P ^b,e,f,g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c Deke Slayton Cancer Center   (United States)

^d TEXAS ONCOLOGY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f Southwest Oncology Group   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adjuvant chemotherapy; Bladder cancer; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; ORGAN PRESERVATION; PATIENT CARE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PERIOPERATIVE CARE; URINARY BLADDER NEOPLASMS;

EID: 31344454239     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.05.004     Document Type: Review

References (49)

1. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients J Clin Oncol 19 3 2001 666 675
2. M.L. Quek, J.P. Stein, and P.E. Clark Natural history of surgically treated bladder carcinoma with extravesical tumor extension Cancer 98 5 2003 955 961
3. J.P. Stein, J. Cai, S. Groshen, and D.G. Skinner Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: the concept of lymph node density J Urol 170 2003 35 41
4. H.W. Herr Superiority of ratio based LN staging for bladder cancer J Urol 169 2003 943 951
5. A. Poulsen, T. Horn, and K. Steven Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall J Urol 160 1998 2015 2019
6. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy J Clin Oncol 21 4 2003 690 696
7. P.J. Sr Loehrer, L.H. Einhorn, and P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
8. C.J. Logothetis, F.H. Dexeus, and L. Finn A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
9. A. Bamias, G. Aravantinos, and C. Deliveliotis Docetaxel and cisplatin with granulocyte colony stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 22 2 2004 220 228
10. A.O. Siefker-Radtke, R.E. Millikan, and S.M. Tu Phase III trial of fluorouracil, interferon alfa-2b and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in metastatic or unresectable urothelial cancer J Clin Oncol 20 5 2002 1361 1367
11. C.N. Sternberg, de Mulder PHM, and J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No 30924. J Clin Oncol 19 10 2001 2638 2646
12. H. Von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
13. B.G. Redman, D.C. Smith, and L. Flaherty Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma J Clin Oncol 16 5 1998 1844 1848
14. D.J. Vaughn, J. Manola, and R. Dreicer Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group Cancer 95 5 2002 1022 1027
15. M. Hussain, U. Vaishampayan, and W. Du Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer J Clin Oncol 19 9 2001 2527 2533
16. J.D. Hainsworth, A.A. Meluch, and S. Litchy Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium Cancer April 26 2005 [Epub ahead of print]
17. G. Carteni, L. Dogliotti, and E. Crucitta Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU) Proc Am Soc Clin Oncol 22 2003 384 (abstr 1543)
18. C.J. Logothetis, D.E. Johnson, and C. Chong Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer: an update J Clin Oncol 6 10 1988 1590 1596
19. D.G. Skinner, J.R. Daniels, and C.A. Russell The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial J Urol 145 3 1991 459 464
20. M. Stockle, W. Meyenburg, and S. Wellek Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study J Urol 148 2 Pt 1 1992 302 306
21. M. Stockle, W. Meyenburg, and S. Wellek Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience J Urol 153 1 1995 47 52
22. U.E. Studer, M. Bacchi, and C. Biedermann Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial J Urol 152 1 1994 81 84
23. F. Freiha, J. Reese, and F.M. Torti A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer J Urol 155 2 1996 495 499
24. C.H. Wei, R.K. Hsieh, and T.J. Chiou Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience J Urol 155 1 1996 118 121
25. A. Bamias, Deliveliotis Ch, and G. Aravantinos Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group J Urol 171 4 2004 1467 1470
26. D.J. Vaughn, J. Manola, and R. Dreicer Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group Cancer 95 5 2002 1022 1027
27. B.G. Redman, D.C. Smith, and L. Flaherty Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma J Clin Oncol 16 1998 1844 1848
28. R.J. Cote, D. Esrig, and S. Groshen P53 and treatment of bladder cancer Nature 385 1997 123 124
29. P.K. Schultz, H.W. Herr, and Z.F. Zhang Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up J Clin Oncol 12 7 1994 1394 1401
30. A.S. Sarkis, D.F. Bajorin, and V.E. Reuter Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol 13 1995 1384 1390
31. J.A. Martinez-Pineiro, M. Gonzalez Martin, and F. Arocena Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study J Urol 153 3 Pt 2 1995 964 973
32. P.U. Malmstrom, E. Rintala, R. Wahlqvist The Nordic Cooperative Bladder Cancer Study Group Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I J Urol 155 6 1996 1903 1906
33. A. Sherif, E. Rintala, and O. Mestad Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2 Scand J Urol Nephrol 36 6 2002 419 425
34. C. Logothetis, D. Swanson, and R. Amato Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of pre-operative and post-operative chemotherapy for invasive bladder carcinoma J Urol 155 4 1996 1241 1245
35. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both pre-operative and post-operative M-VAC J Clin Oncol 19 2001 4005 4013
36. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999;354(9178):533-40. Erratum in: Lancet 1999;354(9190):1650.
37. Hall RR, On Behalf of the International Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, MRC Clinical Trials Unit, London, UK. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002;abstr No. 710.
38. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 9 2003 859 866 Erratum in: N Engl J Med 2003;349(19):1880.
39. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 9373 2003 1927 1934 Review
40. E. Winquist, T.S. Kirchner, and R. Segal Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 2 Pt 1 2004 561 569 Review
41. C.M. Coppin, M.K. Gospodarowicz, K. James The National Cancer Institute of Canada Clinical Trials Group Improved local control of invasive bladder cancer by concurrent cisplatin and pre-operative or definitive radiation J Clin Oncol 14 1996 2901 2907
42. H.W. Herr, D.F. Bajorin, and H.I. Scher Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome J Clin Oncol 16 4 1998 1298 1301
43. C.N. Sternberg, V. Pansadoro, and F. Calabro Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder Ann Oncol 10 11 1999 1301 1305
44. C.N. Sternberg, V. Pansasadoro, and F. Calabro Can patient selection for bladder preservation be based on response to chemotherapy Cancer 97 2003 1644 1652
45. D.S. Kaufman, W.U. Shipley, and P.P. Griffin Selective bladder preservation by combination treatment of invasive bladder cancer N Engl J Med 329 19 1993 1377 1382
46. L.A. Kachnic, D.S. Kaufman, and N.M. Heney Bladder preservation by combined modality therapy for invasive bladder cancer J Clin Oncol 15 3 1997 1022 1029
47. A.L. Zietman, D. Sacco, and U. Skowronski Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors J Urol 170 2003 1772 1776
48. C. Rodel, G.G. Grabenbauer, and R. Kuhn Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 14 2002 3061 3071
49. W.U. Shipley, K.A. Winter, and D.S. Kaufman Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 J Clin Oncol 16 11 1998 3576 3583